

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: [ICC International Cannabis Corp.](#) (the "Issuer").

Trading Symbol: [WRLD.U](#)

Number of Outstanding Listed Securities: [702,887,198 as of June 30, 2019.](#)

Date: [July 02, 2019 \(for the month of June 2019\)](#)

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

[The Issuer continues to evaluate potential marijuana projects and cannabis related companies for potential acquisition and growth. The Issuer continues to concentrate on assembling a robust portfolio of licences globally specializing in the cultivation, extraction and distribution of medical cannabis and CBD products with a specific emphasis on both the European Union and Latin American](#)

regions, and a keen interest in Africa and Australasia, Southeast Asia, and the Pacific Rim.

2. Provide a general overview and discussion of the activities of management.

During the month of **June 2019**, the Issuer:

- Continued to productively collaborate with South African regulators, while optimizing its South African downstream assets and Lesotho-based low-cost cannabis production initiatives.
 - Entered into a definitive agreement with VendaPharm EU LLC to acquire 100 percent of VendaPharm's issued and outstanding shares.
 - Announced the resignation of Michael Martinz as President and Director of the Company and announced the appointment of Mr. Peter Nguyen to its board of directors.
 - Extended the expiry dates of certain common share warrants issued as part of a non-brokered private placement that closed on June 19, 2018. The expiry date of the warrants has been extended to June 19, 2020.
 - Entered into a definitive agreement with to acquire 100 per cent of Grupo Pharma Colombiano Inc. to further augment its LATAM pharmacy distribution network.
 - Completed a Technical Feasibility Study relating to its proposed 150,000 square foot Danish GACP/EU-GMP certified Greenfield cultivation, processing and manufacturing facility.
3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.
Not applicable to the Issuer for the month of June 2019.
 4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.
Not applicable to the Issuer for the month of June 2019.
 5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.
Not applicable to the Issuer for the month of June 2019.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not applicable to the Issuer for the month of **June 2019**.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

On **June 6, 2019** the Issuer announced that it entered into a definitive agreement with VendaPharm EU LLC ("VendaPharm") to acquire 100 per cent of VendaPharm's issued and outstanding shares.

By way of an exclusive distribution and software licensing agreement, VendaPharm controls the international rights to a proprietary THC/CBD dispensing technology and kiosk (the "Vending Machine"), designed to facilitate a contemporary, intuitive and educational purchasing experience for the modern THC/CBD consumer. The Vending Machine is equipped with comprehensive inventory management software, as well as industry leading payment-processing infrastructure, which permits the ready acceptance of both debit and credit cards, in addition to fiat currency.

International Cannabis plans to deploy the Vending Machine into high traffic retail end points and pharmacies across its European downstream network; with the objective of affording the end consumer streamlined access to a variety of branded THC/CBD stock keeping units ("SKUs").

It is anticipated that the deployment of the Vending Machine across ICC's distribution channels will reduce staffing costs, improve accountability, optimize retail space and minimize inventory slippage, all while affording consumers an unobtrusive and technological superior option to purchase desired THC/CBD SKUs.

On Closing, the Issuer shall issue to the Vendors an aggregate number of the Issuer's shares equal to \$2 million, where each Issuer's share has an attributed value equal to the five (5) day volume weighted average price ("VWAP") of an ICC Share on the Exchange prior to the date of issuance (the "Closing Payment Shares"). When issued, 50% of the Closing Payment Shares will be subject to a hold period of six months from the date of issuance and the remaining 50% of the Closing Payment Shares will be subject to a hold period of twelve months from the date of the issuance. The Issuer may also issue additional shares upon the achievement of certain forward looking milestones. A Finder's fee will be paid on the transaction.

On **June 13, 2019** the Issuer announced that it has entered into a definitive agreement to acquire 100 per cent of Grupo Pharma Colombiano Inc. (“Grupo Pharma”), further augmenting its LATAM pharmacy distribution network.

Grupo Pharma controls 75 per cent of an existing pharmacy operation located in the “El Poblado” area of Medellin, Colombia (“Pharmacy Grupo”), which is a centrally located, affluent community that has a population of approximately 128,000 consumers within a nine square mile radius. The area is also a top tourist destination and benefits from the influx of the approximate 550,000 annual visitors that Medellin receives.

The acquisition of Grupo Pharma represents the Issuer’s second flagship Colombian brick and mortar pharmacy operation, with eight additional locations expected to be secured and retrofitted by the end of fiscal 2019.

Pharmacy Grupo is equipped with an experienced operations team, focused on deploying a patient-centric distribution strategy, coupled with optimized supply chain channels. The Issuer plans to drive prescription and brand loyalty to its flagship Colombian pharmacies, while addressing priority medical conditions within LATAM theatre by combining:

- Patented delivery systems and technologies;
- Extensive consumer product goods (“CPG”) and branded product market entrance experience;
- Global scientific expertise; and,
- Comprehensive doctor detailing and educational campaigns

Pharmacy Grupo has established a strong presence and client base servicing the local populous and is now preparing to execute on a comprehensive expansion campaign, targeting high density, consumer friendly zones across the Antioquia region of Northwest Colombia. The Antioquian region is home to approximately 6.6 million inhabitants and is widely revered for its robust healthcare infrastructure, universities and diverse industries.

Grupo Pharma’s flagship pharmacy is equipped with retail, wholesale and on-line distribution channels and boasts the following industry accolades:

- Top 10 individual sales location in all of Antioquia;
- Top 10 vendor of Abbott y LaFranco & Coopidrogas Pharmaceuticals;
- Over 2000 unique SKU’s on offer;
- Referral network of over 400 certified medical professionals;
- 30 minute in-house pharmaceutical delivery and medical visit outreach infrastructure; and,
- Relationships with major pharmaceutical brands

By leveraging proprietary data science techniques and advanced regression analytics derived from demographic and consumer information repositories,

Grupo Pharma has developed a comprehensive expansion stratagem with the objective of capturing increased market penetration across the Antioquia region.

Pending appropriate licensing and regulatory approval, Grupo Pharma's strategic growth plans include introducing premium cannabis flower and cannabidiol ("CBD") related products derived from International Cannabis' library of native Colombian cannabis genetics.

The Issuer's Colombian genetics portfolio consists of 20 unique strains that include both prominent tetrahydrocannabinol ("THC") and CBD varieties, such as:

- Caucana;
- Purpura;
- Medellin Gold; and,
- Maroc

As both the World Health Organization and many countries around the world shift their stance in favour of medical use of CBD-dominant cannabis oils and CBD-derived health and wellness products; the demand for high-yield CBD strains is expected to increase geometrically.

Pharmacy Grupo further bolsters the Issuer's downstream LATAM capabilities by securing a turnkey solution to establish a baseline presence within Colombian's burgeoning medical cannabis and health and wellness verticals.

In conjunction with our data driven LATAM expansion plan, the Company will undertake material efforts to strengthen our Colombian doctor out-reach programs, as well as institute high profile corporate and university drug plan out-reach initiatives. The Issuer will continue to leverage its advanced global downstream capabilities, including its European distribution footprint of 80,000 pharmacies and retail end-points to market premium cannabis under the Company's diverse brands and banners."

On closing, the Issuer shall issue to the shareholders of Grupo Pharma 15 million common shares in the capital of the Issuer. When issued, 50 per cent of the closing payment shares will be subject to a hold period of six months from the date of issuance, and the remaining 50 per cent of the closing payment shares will be subject to a hold period of 12 months from the date of the issuance. The Issuer will also pay C\$230,000.00. A finder's fee is payable on this transaction.

8. Describe the acquisition of new customers or loss of customers.

Not applicable to the Issuer for the month of **June 2019**.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.
Not applicable to the Issuer for the month of June 2019.
10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.
Not applicable to the Issuer for the month of June 2019.
11. Report on any labour disputes and resolutions of those disputes if applicable.
Not applicable to the Issuer for the month of June 2019.
12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.
Not applicable to the Issuer for the month of June 2019.
13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.
Not applicable to the Issuer for the month of June 2019.
14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds
Common Shares	8,064,516 (806,451 of the shares issued were for a finder's fee)	Pursuant to the terms and conditions of a Share Exchange Agreement with Venda Pharm EU LLC.	General working capital purposes.
Common Shares	16,500,000 (1,500,000 of the shares issued were for a finder's fee)	Pursuant to the terms and conditions of a Share Exchange Agreement with Grupo Pharma Colombiano Inc.	General working capital purposes.
Warrants	10,000,000	10,000,000 warrants were originally issued on June 20, 2018 with an expiry date of June 19, 2019, pursuant to a private placement. The Issuer has amended the expiry date of the warrants to June 19, 2020. The exercise price of CDN\$1.00 will remain the same.	General working capital purposes.

15. Provide details of any loans to or by Related Persons.
Not applicable to the Issuer for the month of June 2019.

16. Provide details of any changes in directors, officers or committee members.

On **June 6, 2019**, the Issuer announced the resignation of Michael Martinz as President and Director of the Company and announced the appointment of Mr. Peter Nguyen to its board of directors. Mr. Nguyen currently acts in the capacity of Chief Financial Officer of the Issuer.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are detailed in the Issuer's Management Discussion & Analysis dated January 28, 2019 (the "MD&A"). The MD&A is available on the Issuer's SEDAR profile at www.sedar.com.

[the balance of this page is intentionally blank]

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated July 02, 2019.

Eugene Beukman
Name of Director or Senior
Officer

"Eugene Beukman"
Signature

Director
Official Capacity

<i>Issuer Details</i>	For Month	Date of Report
Name of Issuer	End	YY/MM/DD
ICC International Cannabis Corp	June 2019	19/07/02
Issuer Address		
810 – 789 West Pender Street		
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.
Vancouver, BC V6C 1H	604-687-3141	604-687-2308
Contact Name	Contact Position	Contact Telephone No.
Eugene Beukman	Director	604-782-4191
Contact Email Address	Web Site Address	
Ebeukman@pendergroup.ca	N/A	